Wolfgang Miesbach: FRONTIER4 Long-Term Results Highlight the Promise of Denecimig in Haemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”FRONTIER4 — denecimig (Mim8) long-term data presented at ISTH 2026 in Paris.
Among the clinically relevant prophylaxis updates, OC 02.4 by Jerzy Windyga reported interim safety and efficacy results from FRONTIER4, the long-term extension study of the denecimig (Mim8) programme in haemophilia A.
Denecimig is a next-generation subcutaneous FVIIIa mimetic, optimised for FIXa cofactor activity and thrombin generation.
What sets the programme apart is the dosing flexibility: once weekly, once every two weeks, or once monthly — by patient choice after week 26.
Interim analysis in adults and adolescents (≥12 years, N=365; median observation ~0.5 years):
Efficacy
- Overall estimated mean ABR 0.75, consistently low across all three schedules (QW 0.91, Q2W 0.55, QM 0.74)
- Median observed ABR was zero in every subgroup
- 71.2% with zero treated bleeds
- Low spontaneous bleeds (ABR 0.09) and near-absent target-joint bleeds (ABR 0.01, 97% zero)
- Low ABRs irrespective of FVIII inhibitor status (positive 0.15, negative 0.88)
Safety
- No thromboembolic events
- Injection-site reactions in 1.8% of injections (108/6138); the majority of AEs mild
- No clinical evidence of neutralising anti-denecimig antibodies
Monthly dosing maintained bleed protection comparable to weekly — a genuine opportunity to reduce treatment burden, with low bleed rates holding regardless of inhibitor status.
Congratulations to the investigators and, above all, to the FRONTIER4 participants.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 09:41Girishkumar Modi: Navigating the 2026 Jehovah’s Witness Transfusion Policy Shift in Clinical Practice
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning